Quarterly ResultAug 11, 2026, 07:02 AM
Kardigan Reports Q2 2026 Results, $661M Cash, Advances Clinical Programs
AI Summary
Kardigan, Inc. reported its financial results for the second quarter ended June 30, 2026, alongside significant progress in its clinical development programs. The company ended the quarter with a strong cash position of $660.7 million, following a $460 million initial public offering in June 2026, which extends its cash runway through multiple data readouts and the initiation of Phase 3 clinical trials. While the net loss increased to $116.2 million due to higher R&D expenses of $56.4 million, this reflects the advancement of its three late-stage programs: Danicamtiv, Ataciguat, and Tonlamarsen, all of which have key data readouts anticipated in the first half of 2027.
Key Highlights
- Cash, cash equivalents, and investments totaled $660.7 million as of June 30, 2026.
- Net proceeds from the initial public offering (IPO) in June 2026 were $460 million.
- Net loss for Q2 2026 was $116.2 million, compared to $57.4 million in Q2 2025.
- Research and development expenses rose to $56.4 million in Q2 2026 from $35.8 million in Q2 2025.
- Danicamtiv KINSHIP-DCM Phase 3 enrollment is underway; Phase 2b data expected 1H 2027.
- Ataciguat KATALYST-AV Phase 2b topline data is expected in the first half of 2027.
- Tonlamarsen KARDINAL-ASH Phase 2 topline data is expected in the first half of 2027.
- Current cash runway supports advancement through multiple data readouts and Phase 3 initiations.
Price Impact
More from KARD